Tiny study probes why clozapine beats other schizophrenia drugs

NCT ID NCT05741502

Terminated Knowledge-focused Sponsor: Ohio State University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study aimed to compare the effects of clozapine versus other antipsychotic medications on inflammation in people with treatment-resistant schizophrenia. Researchers measured inflammatory markers like interleukin-6 in a small group of participants. The study was terminated early with only 5 people enrolled, so no firm conclusions can be drawn.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Clozapine
What this could lead to: If successful, this could help explain why clozapine works better for some people with treatment-resistant schizophrenia, potentially guiding future treatments.
What could go wrong: This was a very small, terminated study with only 5 participants, so results are not reliable. It was exploratory, meaning it was designed to generate ideas, not prove anything.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TREATMENT-RESISTANT SCHIZOPHRENIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Schizophrenia, Treatment-Resistant treatment-refractory schizophrenia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TREATMENT-RESISTANT SCHIZOPHRENIA

Contacts and locations

Locations

Ohio State University Harding Hospital

Columbus, Ohio, 43210, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.